ROS-induced nanotherapeutic approach for ovarian cancer treatment based on the combinatorial effect of photodynamic therapy and DJ-1 gene suppression

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 8, 2015, Pages 1961-1970

  Schumann, Canan ^a   Taratula, Olena ^a   Khalimonchuk, Oleh ^b   Palmer, Amy L ^a   Cronk, Lauren M ^a   Jones, Carson V ^a   Escalante, Cesar A ^a   Taratula, Oleh ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

DJ 1; Ovarian cancer; Photodynamic therapy; ROS; siRNA therapy

Indexed keywords

CELLS; CYTOLOGY; DISEASES; INFRARED DEVICES; NITROGEN COMPOUNDS; PHOTODYNAMIC THERAPY; PHOTOSENSITIZERS; PROTEINS; SURGERY; TUMORS;

COMBINATORIAL APPROACH; DJ-1; OVARIAN CANCERS; OVARIAN CARCINOMA CELL; PHOTODYNAMIC THERAPY (PDT); ROS; SIRNA THERAPIES; THERAPEUTIC EFFICACY;

GENE THERAPY;

DENDRIMER; DJ 1 PROTEIN; MESSENGER RNA; PHTHALOCYANINE; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; DRUG CARRIER; INDOLE DERIVATIVE; NANOMATERIAL; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; PHOTOSENSITIZING AGENT; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DJ 1 GENE; ERADICATION THERAPY; FEMALE; FLOW CYTOMETRY; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NANOMEDICINE; NONHUMAN; ONCOGENE; OVARY CANCER; OVARY CARCINOMA; PHOTODYNAMIC THERAPY; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; PHOTOCHEMOTHERAPY; RNAI THERAPEUTICS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, NUDE; NANOSTRUCTURES; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; OVARY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; RNAI THERAPEUTICS;

EID: 84951187770     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.07.005     Document Type: Article

References (49)

1. Cancer facts and figures, American Cancer Society http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/.
2. Lim M.C., Seo S.S., Kang S., Kim S.K., Kim S.H., Yoo C.W., et al. Intraoperative image-guided surgery for ovarian cancer. Quant Imaging Med Surg 2012, 2:114-117.
3. van Dam G.M., Themelis G., Crane L.M., Harlaar N.J., Pleijhuis R.G., Kelder W., et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011, 17:1315-1319.
4. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259.
5. Lim M.C., Kang S., Lee K.S., Han S.S., Park S.J., Seo S.S., et al. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol 2009, 112:28-34.
6. Dowdy S.C., Mariani A., Cliby W.A., Haddock M.G., Petersen I.A., Sim F.H., et al. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol 2006, 101:280-286.
7. Elias D., Goere D., Dumont F., Honore C., Dartigues P., Stoclin A., et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 2014, 50:332-340.
8. Yap O.W., Kapp D.S., Teng N.N., Husain A. Intraoperative radiation therapy in recurrent ovarian cancer. Int J Radiat Oncol Biol Phys 2005, 63:1114-1121.
9. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011, 61:250-281.
10. Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat Rev Cancer 2003, 3:380-387.
11. Gorrini C., Harris I.S., Mak T.W. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013, 12:931-947.
12. Hileman E.O., Liu J., Albitar M., Keating M.J., Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004, 53:209-219.
13. Das T.P., Suman S., Damodaran C. Induction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells. Mol Carcinog 2014, 53:537-547.
14. Friedberg J.S. Photodynamic therapy for malignant pleural mesothelioma: the future of treatment?. Expert Rev Respir Med 2011, 5:49-63.
15. Rigual N.R., Shafirstein G., Frustino J., Seshadri M., Cooper M., Wilding G., et al. Adjuvant intraoperative photodynamic therapy in head and neck cancer. JAMA Otolaryngol Head Neck Surg 2013, 139:706-711.
16. Zilidis G., Aziz F., Telara S., Eljamel M.S. Fluorescence image-guided surgery and repetitive photodynamic therapy in brain metastatic malignant melanoma. Photodiagnosis Photodyn Ther 2008, 5:264-266.
17. Casas A., Di Venosa G., Hasan T., Al B. Mechanisms of resistance to photodynamic therapy. Curr Med Chem 2011, 18:2486-2515.
18. Agnani D., Camacho-Vanegas O., Camacho C., Lele S., Odunsi K., Cohen S., et al. Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. J Ovarian Res 2011, 4:18.
19. Cao J., Lou S., Ying M., Yang B. DJ-1 as a human oncogene and potential therapeutic target. Biochem Pharmacol 2015, 93:241-250.
20. Hu Y., Rosen D.G., Zhou Y., Feng L., Yang G., Liu J., et al. Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J Biol Chem 2005, 280:39485-39492.
21. Shim G.S., Manandhar S., Shin D.H., Kim T.H., Kwak M.K. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radic Biol Med 2009, 47:1619-1631.
22. Clements C.M., McNally R.S., Conti B.J., Mak T.W., Ting J.P.Y. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A 2006, 103:15091-15096.
23. Hod Y. Differential control of apoptosis by DJ-1 in prostate benign and cancer cells. J Cell Biochem 2004, 92:1221-1233.
24. Fan J., Ren H.G., Jia N.L., Fei E., Zhou T., Jiang P., et al. DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J Biol Chem 2008, 283:4022-4030.
25. Sekkat N., van den Bergh H., Nyokong T., Lange N. Like a bolt from the blue: phthalocyanines in biomedical optics. Molecules 2012, 17:98-144.
26. Taratula O., Patel M., Schumann C., Naleway M.A., Pang A.J., He H. Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy. Int J Nanomedicine 2015, 10:2347-2362.
27. Taratula O., Schumann C., Naleway M.A., Pang A.J., Chon K.J. A multifunctional theranostic platform based on phthalocyanine-loaded dendrimer for image-guided drug delivery and photodynamic therapy. Mol Pharm 2013, 10:3946-3958.
28. Huang C., Li M., Chen C., Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets 2008, 12:637-645.
29. Seth S., Johns R., Templin M.V. Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects. Ther Deliv 2012, 3:245-261.
30. Taratula O., Schumann C., Duong T., Taylor K.L., Taratula O. Dendrimer-encapsulated naphthalocyanine as a single agent-based theranostic nanoplatform for near-infrared fluorescence imaging and combinatorial anticancer phototherapy. Nanoscale 2015, 7:3888-3902.
31. Dani R.K., Schumann C., Taratula O. Temperature-tunable iron oxide nanoparticles for remote-controlled drug release. AAPS PharmSciTech 2014, 15:963-972.
32. Shah V., Taratula O., Garbuzenko O.B., Taratula O.R., Rodriguez-Rodriguez L., Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res 2013, 19:6193-6204.
33. Dickinson B.C., Huynh C., Chang C.J. A palette of fluorescent probes with varying emission colors for imaging hydrogen peroxide signaling in living cells. J Am Chem Soc 2010, 132:5906-5915.
34. Mishra G.P., Nguyen D., Alani A.W. Inhibitory effect of paclitaxel and rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade. Mol Pharm 2013, 10:2071-2078.
35. Taratula O., Garbuzenko O.B., Kirkpatrick P., Pandya I., Savla R., Pozharov V.P., et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 2009, 140:284-293.
36. Taratula O., Savla R., He H., Minko T. Poly (propyleneimine) dendrimers as potential siRNA delivery nanocarrier: from structure to function. Int J Nanotechnol 2011, 8:35-62.
37. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
38. Kojima C., Toi Y., Harada A., Kono K. Preparation of poly(ethylene glycol)-attached dendrimers encapsulating photosensitizers for application to photodynamic therapy. Bioconjug Chem 2007, 18:663-670.
39. Arencibia J.M., Bajo A.M., Schally A.V., Krupa M., Chatzistamou I., Nagy A. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anticancer Drugs 2002, 13:949-956.
40. Volker P., Grundker C., Schmidt O., Schulz K.D., Emons G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 2002, 186:171-179.
41. Fazal N., Al-Ghoul W.M. Thermal injury-plus-sepsis contributes to a substantial deletion of intestinal mesenteric lymph node CD4 T cell via apoptosis. Int J Biol Sci 2007, 3:393-401.
42. Gan L., Johnson D.A., Johnson J.A. Keap1-Nrf2 activation in the presence and absence of DJ-1. Eur J Neurosci 2010, 31:967-977.
43. Honbou K., Suzuki N.N., Horiuchi M., Niki T., Taira T., Ariga H., et al. The crystal structure of DJ-1, a protein related to male fertility and Parkinson's disease. J Biol Chem 2003, 278:31380-31384.
44. Inberg A., Linial M. Protection of pancreatic beta-cells from various stress conditions is mediated by DJ-1. J Biol Chem 2010, 285:25686-25698.
45. Ismail I.A., Shakor A.B., Hong S.H. DJ-1 protects breast cancer cells against 2'-benzoyloxycinnamaldehyde-induced oxidative stress independent of Nrf2. J Cell Physiol 2015, 230:2262-2269.
46. Liu H., Wang M., Li M., Wang D., Rao Q., Wang Y., et al. Expression and role of DJ-1 in leukemia. Biochem Biophys Res Commun 2008, 375:477-483.
47. MacKeigan J.P., Clements C.M., Lich J.D., Pope R.M., Hod Y., Ting J.P. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 2003, 63:6928-6934.
48. Raninga P.V., Trapani G.D., Tonissen K.F. Cross talk between two antioxidant systems, thioredoxin and DJ-1: consequences for cancer. Oncoscience 2014, 1:95-110.
49. Zhu H., Liao S.D., Shi J.J., Chang L.L., Tong Y.G., Cao J., et al. DJ-1 mediates the resistance of cancer cells to dihydroartemisinin through reactive oxygen species removal. Free Radic Biol Med 2014, 71:121-132.